Ocular Therapeutix (OCUL) Cash from Operations (2013 - 2026)

Ocular Therapeutix's Cash from Operations history runs 14 years deep, the most recent figure standing at 65993000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 47.73% year-over-year to 65993000.0 in Q1 2026; TTM through Mar 2026 was 226205000.0, a 55.51% decrease from a year earlier, with the FY2025 full-year figure at 204883000.0, down 52.13% from the prior year.
• Cash from Operations declined to 65993000.0 in Q1 2026 per OCUL's latest filing, from 54249000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 7732000.0 in Q3 2023 and bottomed at 65993000.0 in Q1 2026.
• The 5-year median for Cash from Operations is 24802000.0 (2024), against an average of 31493529.41.
• Across the five-year window, Cash from Operations surged 45.77% in 2022 and plunged 372.83% in 2024, its largest moves.
• Year by year, Cash from Operations stood at 16958000.0 in 2022, then slumped by 32.41% to 22454000.0 in 2023, then slumped by 75.6% to 39429000.0 in 2024, then tumbled by 37.59% to 54249000.0 in 2025, then declined by 21.65% to 65993000.0 in 2026.
• Per Business Quant, the three latest OCUL Cash from Operations figures stand at 65993000.0 (Q1 2026), 54249000.0 (Q4 2025), and 50725000.0 (Q3 2025).